{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2004"],"data_sharing_plan":["IPD Sharing (as of March 2018): No"],"condition":["Colon cancer","Colorectal Cancer","Colorectal Neoplasms","Liver Neoplasms","Neoplasms"],"disease":["Colon Cancer","Colorectal Cancer","Colorectal Neoplasms","Liver Neoplasms","Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2015703"],"location":["United States"],"study_start_month":["7"],"keyword":["Colorectal Tumors","Rectum tumors","Hepatic Cancer","Rectum Neoplasms","Colon tumors","Metastatic to the liver","Rectum carcinoma","Rectum Cancer","Colorectal Carcinoma","Colon Neoplasms","Liver cancer","Liver Tumors","Colorectal cancer metastases to liver","Hepatic Neoplasms","Hepatic tumors","Colon carcinoma"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver","description":"This study is an open-label study. It has two stages. Stage 1 is a dose escalation phase of the study to determine and evaluate the safety and tolerability of repeated treatments with a genetically engineered herpes simplex virus NV1020 administered locoregionally to the liver.\nStage 2 is to evaluate the dose found in Stage 1 to be \"optimally tolerated\". Stage 2 is to assess the efficacy of the optimally tolerated dose of NV1020 by itself and in combination with second-line chemotherapy.\nAssignment to Stage 1 or Stage 2 of the study is determined by when the patient enters the study.","dates":{"creation":"2004-07-15"},"accession":"2015703","cross_references":{"ClinicalTrials___gov":["NCT00149396"]}}